Literature DB >> 19949618

Cardiac functional evaluation using vector velocity imaging after chemotherapy including anthracyclines in children with cancer.

Jong Hun Park1, Yeo Hyang Kim, Myung Chul Hyun, Heung Sik Kim.   

Abstract

BACKGROUND AND OBJECTIVES: Anthracyclines are effective drugs that are widely used in pediatric cancer treatment. Previous studies have demonstrated that exposure to low-dose anthracyclines (<300 mg/m(2)) induces a progressive decrease in cardiac function during long-term follow-up. The goal of this study was to assess left ventricular function using vector velocity imaging (VVI) in children undergoing low-dose anthracycline therapy. SUBJECTS AND METHODS: We examined 14 asymptomatic patients who had been treated with anthracyclines and had normal fractional shortening (FS) and ejection fraction (EF). In all of the patients, standard two-dimensional (2D) pulsed and tissue Doppler echocardiographic measurements were taken from an apical 4-chamber view. The peak myocardial velocity, peak strain rate (SR), peak strain, and displacement were obtained from VVI. Data were compared with 14 age-matched healthy controls.
RESULTS: From the regional wall motion analysis using VVI in the left ventricle, the peak myocardial velocity and displacement of the lateral wall were increased significantly more than the septum, and there were no significant differences between the patients and the controls. Although systolic strain, and the systolic and diastolic SRs showed no significant differences between the septum and lateral wall in the controls, those of septum, in the patients, were decreased significantly more than those of lateral wall (p<0.05). In comparison with the controls, these changes in septal strain and SRs of patients were significant (p<0.05).
CONCLUSION: Anthracycline therapy, even low-dose, can induce changes in regional wall function before global dysfunction. Also, the strain and SR obtained from VVI may be useful for early detection of these changes.

Entities:  

Keywords:  Anthracyclines; Strain

Year:  2009        PMID: 19949618      PMCID: PMC2771831          DOI: 10.4070/kcj.2009.39.9.352

Source DB:  PubMed          Journal:  Korean Circ J        ISSN: 1738-5520            Impact factor:   3.243


  16 in total

1.  Diastolic or systolic left and right ventricular impairment at moderate doses of anthracycline? A 1-year follow-up study of women.

Authors:  Y Cottin; C Touzery; B Coudert; S Richebourg; M Cohen; M Toubeau; P Louis; J E Wolf; F Brunotte
Journal:  Eur J Nucl Med       Date:  1996-05

2.  Guidelines for cardiac monitoring of children during and after anthracycline therapy: report of the Cardiology Committee of the Childrens Cancer Study Group.

Authors:  L J Steinherz; T Graham; R Hurwitz; H M Sondheimer; R G Schwartz; E M Shaffer; G Sandor; L Benson; R Williams
Journal:  Pediatrics       Date:  1992-05       Impact factor: 7.124

Review 3.  Doxorubicin-induced cardiomyopathy.

Authors:  P K Singal; N Iliskovic
Journal:  N Engl J Med       Date:  1998-09-24       Impact factor: 91.245

4.  Relationship between cumulative anthracycline dose and late cardiotoxicity in childhood acute lymphoblastic leukemia.

Authors:  K Nysom; K Holm; S R Lipsitz; S M Mone; S D Colan; E J Orav; S E Sallan; J H Olsen; H Hertz; J R Jacobsen; S E Lipshultz
Journal:  J Clin Oncol       Date:  1998-02       Impact factor: 44.544

5.  Tissue Doppler imaging in detection of myocardial dysfunction in survivors of childhood cancer treated with anthracyclines.

Authors:  L Kapusta; J M Thijssen; J Groot-Loonen; T Antonius; J Mulder; O Daniëls
Journal:  Ultrasound Med Biol       Date:  2000-09       Impact factor: 2.998

6.  Functional myocardial impairment in children treated with anthracyclines for cancer.

Authors:  S T Yeung; C Yoong; J Spink; A Galbraith; P J Smith
Journal:  Lancet       Date:  1991-04-06       Impact factor: 79.321

7.  Female sex and higher drug dose as risk factors for late cardiotoxic effects of doxorubicin therapy for childhood cancer.

Authors:  S E Lipshultz; S R Lipsitz; S M Mone; A M Goorin; S E Sallan; S P Sanders; E J Orav; R D Gelber; S D Colan
Journal:  N Engl J Med       Date:  1995-06-29       Impact factor: 91.245

8.  Doxorubicin-induced congestive heart failure in adults.

Authors:  M M Haq; S S Legha; J Choksi; G N Hortobagyi; R S Benjamin; M Ewer; M Ali
Journal:  Cancer       Date:  1985-09-15       Impact factor: 6.860

9.  Myocardial dysfunction late after low-dose anthracycline treatment in asymptomatic pediatric patients.

Authors:  Javier Ganame; Piet Claus; Anne Uyttebroeck; Marleen Renard; Jan D'hooge; Bart Bijnens; George R Sutherland; Bénédicte Eyskens; Luc Mertens
Journal:  J Am Soc Echocardiogr       Date:  2007-07-02       Impact factor: 5.251

10.  Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood.

Authors:  S E Lipshultz; S D Colan; R D Gelber; A R Perez-Atayde; S E Sallan; S P Sanders
Journal:  N Engl J Med       Date:  1991-03-21       Impact factor: 91.245

View more
  3 in total

Review 1.  Cardiotoxicity due to chemotherapy: role of cardiac imaging.

Authors:  Frédéric Poulin; Paaladinesh Thavendiranathan
Journal:  Curr Cardiol Rep       Date:  2015-03       Impact factor: 2.931

Review 2.  Late Cardiotoxicity: Issues for Childhood Cancer Survivors.

Authors:  Jyothsna Akam-Venkata; Vivian I Franco; Steven E Lipshultz
Journal:  Curr Treat Options Cardiovasc Med       Date:  2016-07

Review 3.  Natural history of myocardial deformation in children, adolescents, and young adults exposed to anthracyclines: Systematic review and meta-analysis.

Authors:  Mirela Tuzovic; Pei-Tzu Wu; Samuel Kianmahd; Kim-Lien Nguyen
Journal:  Echocardiography       Date:  2018-03-30       Impact factor: 1.874

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.